95.23 - 97.14
55.47 - 103.81
1.63M / 1.80M (Avg.)
55.57 | 1.74
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
88831098.78%
Revenue growth above 1.5x RGLD's 79.89%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
88831098.78%
Gross profit growth above 1.5x RGLD's 128.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
392.41%
EBIT growth below 50% of RGLD's 2017.53%. Michael Burry would suspect deeper competitive or cost structure issues.
392.41%
Operating income growth under 50% of RGLD's 2017.53%. Michael Burry would be concerned about deeper cost or sales issues.
-377.97%
Negative net income growth while RGLD stands at 20.95%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-350.00%
Negative EPS growth while RGLD is at 15.37%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-350.00%
Negative diluted EPS growth while RGLD is at 15.76%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
285.84%
OCF growth above 1.5x RGLD's 53.24%. David Dodd would confirm a clear edge in underlying cash generation.
285.84%
FCF growth above 1.5x RGLD's 189.50%. David Dodd would verify if the firm’s strategic investments yield superior returns.
355.10%
10Y revenue/share CAGR under 50% of RGLD's 1482.82%. Michael Burry would suspect a lasting competitive disadvantage.
355.10%
5Y revenue/share CAGR above 1.5x RGLD's 1.30%. David Dodd would look for consistent product or market expansions fueling outperformance.
355.10%
3Y revenue/share CAGR at 50-75% of RGLD's 634.88%. Martin Whitman would question if the firm lags behind competitor innovations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.75%
Negative equity/share CAGR over 10 years while RGLD stands at 558.30%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-3.75%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-3.75%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-137.72%
We cut SG&A while RGLD invests at 11.50%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.